Literature DB >> 16809725

Rethinking risk-benefit assessment for phase I cancer trials.

Steven Joffe1, Franklin G Miller.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16809725     DOI： 10.1200/JCO.2005.04.9296

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  35 in total

1.  Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements.

Authors:  Inmaculada de Melo-Martín; Dolan Sondhi; Ronald G Crystal
Journal:  Mol Ther       Date:  2012-06       Impact factor: 11.454

2.  Extending clinical equipoise to phase 1 trials involving patients: unresolved problems.

Authors:  James A Anderson; Jonathan Kimmelman
Journal:  Kennedy Inst Ethics J       Date:  2010-03

3.  Rethinking risk assessment for emerging technology first-in-human trials.

Authors:  Anna Genske; Sabrina Engel-Glatter
Journal:  Med Health Care Philos       Date:  2016-03

4.  Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.

Authors:  Rajul K Jain; J Jack Lee; David Hong; Maurie Markman; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.

Authors:  Rebecca D Pentz; Margaret White; R Donald Harvey; Zachary Luke Farmer; Yuan Liu; Colleen Lewis; Olga Dashevskaya; Taofeek Owonikoko; Fadlo R Khuri
Journal:  Cancer       Date:  2012-01-31       Impact factor: 6.860

Review 6.  Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009.

Authors:  Valerie A Jenkins; John L Anderson; Lesley J Fallowfield
Journal:  Support Care Cancer       Date:  2010-03-04       Impact factor: 3.603

7.  The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials.

Authors:  Daniel P Sulmasy; Alan B Astrow; M Kai He; Damon M Seils; Neal J Meropol; Ellyn Micco; Kevin P Weinfurt
Journal:  Cancer       Date:  2010-08-01       Impact factor: 6.860

8.  Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials.

Authors:  Fay J Hlubocky; Nancy E Kass; Debra Roter; Susan Larson; Kristen E Wroblewski; Jeremy Sugarman; Christopher K Daugherty
Journal:  J Oncol Pract       Date:  2018-05-22       Impact factor: 3.840

9.  Developing a Model of the Benefits and Burdens of Research Participation in Cancer Clinical Trials.

Authors:  Connie M Ulrich; Kathleen A Knafl; Sarah J Ratcliffe; Therese S Richmond; Christine Grady; Claiborne Miller-Davis; Gwenyth R Wallen
Journal:  AJOB Prim Res       Date:  2012

Review 10.  Phase 0 clinical trials: conceptions and misconceptions.

Authors:  Shivaani Kummar; Larry Rubinstein; Robert Kinders; Ralph E Parchment; Martin E Gutierrez; Anthony J Murgo; Jay Ji; Barbara Mroczkowski; Oxana K Pickeral; Mel Simpson; Melinda Hollingshead; Sherry X Yang; Lee Helman; Robert Wiltrout; Jerry Collins; Joseph E Tomaszewski; James H Doroshow
Journal:  Cancer J       Date:  2008 May-Jun       Impact factor: 3.360
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.